Document is current
Any future updates will be listed below
-
Authors
Matsuoka, Katsuyoshi https://orcid.org/0000-0002-2950-7660
Hisamatsu, Tadakazu https://orcid.org/0000-0002-1178-3536
Mikami, Yohei https://orcid.org/0000-0001-5104-4415
Yamamoto, Takayuki https://orcid.org/0000-0001-7551-5568
Motoya, Satoshi https://orcid.org/0000-0002-4194-8493
Shinzaki, Shinichiro https://orcid.org/0000-0002-7051-618X
Iwakiri, Ryuichi https://orcid.org/0000-0001-7911-9669
Sugiura, Kenkichi https://orcid.org/0000-0002-0912-2384
Nishimura, Kunihiko https://orcid.org/0000-0002-5288-9142
Kajita, Mika https://orcid.org/0000-0002-6101-8912
Fernandez, Jovelle L. https://orcid.org/0000-0001-5013-9789
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03824561 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
https://doi.org/10.1007/s12325-023-02500-6
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 12 December 2022
Accepted: 21 March 2023
First Online: 4 May 2023
